Search Results
Dec 11, 2025, 23:50 ET Now Is Yours: Huawei Mate X7'yi Yenilikçi Ürünlerden Oluşan Yeni Bir Seriyle Birlikte Piyasaya Sürüyor
ortamlarda canlı ayrıntıları hassas bir şekilde yakalar. Dayanıklılık için tasarlanan cihaz, Ultra Dayanıklı Kristal Zırh Kunlun Camdan yapılmış bir dış ekran, Gelişmiş Hassas Menteşeler ve 3 Katmanlı Kompozit Ultra Dayanıklı Yapı ve daha fazlasını içeren tescilli bir Ultra Güvenilir Katlanabilir Mimari
More news about: HUAWEI
Dec 09, 2025, 19:26 ET Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody
al. 2024 Update of Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout Part I: Recommendations for General Patients. Int J Rheum Dis. 2025;28(7):e70375.
More news about: Innovent Biologics
Dec 09, 2025, 16:00 ET Cirius Therapeutics to Highlight Cardiometabolic Benefits of CIR-0602K at Global Cardiovascular Clinical Trialists (CVCT) Forum 2025
2 Harrison, et al., J Hepat, 2020; 3 Despres, et al., NEJM, 1996; 4 Kumar, et al., Diab Vasc Dis Res, 2019; 5 Harrison, et al., Hepat, 2024; 6 Abufarha, et al., ADA Scientific Sessions, 2025; 7Abufarha,
More news about: Cirius Therapeutics
Dec 06, 2025, 12:28 ET Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
Scheffer IE, et al. Epilepsia. 2025;00:1-10Gallop K, et al. Epilepsy Behav. 2021;124:10824 Scheffer IE et al. Nat Rev Dis Primers 2024;10:61 Surdi P, et al. Epilepsia. 2024;65(11):3279-3292 Samanta D, et al. Epilepsy Behav. 2025;170:110472 Dlugos
More news about: H. Lundbeck A/S
Dec 06, 2025, 12:25 ET Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
Scheffer IE, et al. Epilepsia. 2025;00:1-10Gallop K, et al. Epilepsy Behav. 2021;124:10824 Scheffer IE et al. Nat Rev Dis Primers 2024;10:61 Surdi P, et al. Epilepsia. 2024;65(11):3279-3292 Samanta D, et al. Epilepsy Behav. 2025;170:110472 Dlugos
More news about: H. Lundbeck A/S
Dec 05, 2025, 17:45 ET AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study
NCT05039099).1Maier M et al., Sci Transl Med. 2018;10(470).2Marlow TR et al., Neurobiol Dis. 2025;216:107124.About AP-101AP-101 is an investigational human-derived antibody directed against misfolded superoxide dismutase
More news about: AL-S Pharma AG
Dec 05, 2025, 13:30 ET HALPER SADEH LLC ENCOURAGES THE WALT DISNEY COMPANY SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of The Walt Disney Company (NYSE: DIS) breached their fiduciary duties to shareholders.
More news about: Halper Sadeh LLP
Dec 05, 2025, 09:00 ET Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
Belousova E, Benedik MP, et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet J Rare Dis. 2018;13(1):157.6 Tuberous
More news about: Jazz Pharmaceuticals plc
Dec 04, 2025, 05:51 ET UPM and Sappi have signed a non-binding letter of intent to form a graphic paper Joint Venture
reported and excluding UPM Communication Papers. The figures do not include the impact of forming the joint venture, any transaction costs, synergies or dis-synergies or project costs.Transaction subject to merger control and other conditionsNegotiations regarding the details of the Joint
More news about: UPM-Kymmene Oyj
Dec 03, 2025, 03:00 ET IS Decisions simplifie la protection des identités Active Directory avec UserLock 13.0
sécurisée. « La majorité des infrastructures informatiques repose encore sur Active Directory », déclare François Amigorena, CEO et fondateur d'IS Decisions. « UserLock 13.0 aide les équipes informatiques à protéger les identités qu'elles utilisent déjà, sans perturber les systèmes essentiels.
More news about: IS Decisions
Dec 02, 2025, 08:25 ET DriveNets to Showcase Highest-Performance AI Networking Solutions at AI Summit NY
and minimum deployment fine-tuning to ensure optimized AI workload performance.In addition, DriveNets Deployment Infrastructure Services (DIS) supports AI cluster architecture design and end-to-end physical installations that accelerate deployment time while maximizing infrastructure deployment.
More news about: DriveNets
Dec 01, 2025, 19:35 ET Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Wildsmith K, et al., Anti-tau therapeutic antibody, E2814, reduces early and late tau pathology biomarkers in patients with DIAD. J Prev Alzheimers Dis 2025; 1 (12), 13.Horie, K. et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease. Nat Med. 31,
More news about: Eisai Inc.
Nov 20, 2025, 14:35 ET PioCreat, Formnext 2025'te Tam Spektrumlu 3D Baskı Çözümlerini Tanıtıyor
yükseltilmiş LCD ekran, hızı, netliği ve uzun vadeli kararlılığı daha da artırır. Bu çözümler bir araya geldiğinde, klinisyenlerin ve diş laboratuvarlarının tedavi süresini önemli ölçüde kısaltmasına yardımcı olur. 2. Medikal O&P Çözümleri
More news about: PioCreat 3D
Nov 20, 2025, 12:00 ET MyOme Launches First Integrated Polygenic Risk Score for Prostate Cancer to Advance Early Detection and Personalized Prevention
Tuffaha H, Edmunds K, Fairbairn D, et al. Guidelines for genetic testing in prostate cancer: a scoping review.Prostate Cancer Prostatic Dis. 2024;27:594–603. MyOme Internal Data on File. McHugh JK, Bancroft EK, Saunders E, et al. Assessment
More news about: MyOme, Inc
Nov 19, 2025, 04:00 ET FutureDial erweitert seine globale Reichweite mit neuen Automatisierungszentren nach dem Mobile Disrupt Innovation Award
Center-Expertise aufbauen und einsetzen. "Wir von DIS-CONNECT sind sehr stolz darauf, die Expansion von FutureDial nach Deutschland zu unterstützen", sagt Georg Dis, Geschäftsführer und Gründer der DIS-CONNECT GmbH. "Das Engagement von FutureDial für Qualität und Innovation setzt
More news about: FUTUREDIAL INCORPORATED
Nov 19, 2025, 04:00 ET FutureDial Expands Global Reach with New Automation Solution Centers Following Mobile Disrupt Innovation Award
Germany," said Georg Dis, CEO and Founder of DIS-CONNECT GmbH. "FutureDial's commitment to quality and innovation sets the standard in the industry, and together we're delivering next-generation automation and intelligence to customers through our European Solution Center. DIS-CONNECT's Service Solutions,
More news about: FUTUREDIAL INCORPORATED
Nov 19, 2025, 04:00 ET FutureDial Expands Global Reach with New Automation Solution Centers Following Mobile Disrupt Innovation Award
Germany," said Georg Dis, CEO and Founder of DIS-CONNECT GmbH. "FutureDial's commitment to quality and innovation sets the standard in the industry, and together we're delivering next-generation automation and intelligence to customers through our European Solution Center. DIS-CONNECT's Service Solutions,
More news about: FUTUREDIAL INCORPORATED
Nov 19, 2025, 04:00 ET フューチャーダイヤル、モバイル・ディスラプト・イノベーション・アワード（Mobile Disrupt Innovation Award）受賞を受け、新たな自動化ソリューション・センターを開設し、グローバル展開を拡大
Centerのスタッフ配置と設備の整備を行っています。日本では、フューチャーダイヤルが日本およびアジア市場に合わせたソリューション・センターの専門知識を構築し、展開します。 「DIS-CONNECTはフューチャーダイヤルのドイツへの進出を支援できることを非常に誇りに思います」とDIS-CONNECT GmbHのCEO兼創設者であるGeorg Dis氏は述べています。「フューチャーダイヤルの品質と革新への取り組みは業界の標準を確立しており、私たちは協力して、European Solution Centerを通じて次世代の自動化とインテリジェンスを顧客に提供しています。DIS-CONNECTのサービス・ソリューション、AI Decision Matrix、フューチャーダイヤルの自動化システムは、新しい強力な方法で市場に革命をもたらしています。」
More news about: FUTUREDIAL INCORPORATED
Nov 19, 2025, 04:00 ET FutureDial étend sa portée mondiale avec de nouveaux centres de solutions d'automatisation après avoir reçu le prix de l'innovation Mobile Disrupt
solutions adapté aux marchés japonais et asiatiques. "Chez DIS-CONNECT, nous sommes extrêmement fiers de soutenir l'expansion de FutureDial en Allemagne", a déclaré Georg Dis, PDG et fondateur de DIS-CONNECT GmbH. "L'engagement de FutureDial en matière de qualité et d'innovation
More news about: FUTUREDIAL INCORPORATED
Nov 19, 2025, 04:00 ET FutureDial amplía su alcance global con nuevos centros de soluciones de automatización
especializado y adaptado a los mercados japonés y asiático. "En DIS-CONNECT estamos muy orgullosos de apoyar la expansión de FutureDial en Alemania", declaró Georg Dis, consejero delegado y fundador de DIS-CONNECT GmbH. "El compromiso de FutureDial con la calidad y la innovación marca
More news about: FUTUREDIAL INCORPORATED
Nov 18, 2025, 08:45 ET Kansas Museum of History Reopens After Major Renovation
planning and content strategy to exhibit fabrication and audio-visual integration. Bringing the project to life was a deeply collaborative effort, with DI's exhibit designers working closely with museum and Historical Society staff. The refreshed format features a hub-and-spoke layout
More news about: Dimensional Innovations
Nov 17, 2025, 16:15 ET BetterInvesting™ Magazine Update on Intuit Inc. (NASDAQ: INTU) and The Walt Disney Company (NYSE: DIS)
The Walt Disney Company (NYSE: DIS), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective.
More news about: BetterInvesting
Nov 17, 2025, 08:05 ET New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
15 Husted J.A., et al. Occurrence and correlates of fatigue in psoriatic arthritis. Ann Rheum Dis, 2008:68(10), 1553–1558. Available at: https://doi.org/10.1136/ard.2008.098202. Accessed March 2025.
More news about: Johnson & Johnson
Nov 11, 2025, 07:35 ET DriveNets to Showcase its Fabric-Scheduled Ethernet Technology at SC25
Stop by booth 3229 to meet DriveNets' AI networking and infrastructure services (DIS) experts and learn how DriveNets' Network Cloud-AI: Provides an end-to-end AI Ethernet solution
More news about: DriveNets
Nov 10, 2025, 08:46 ET Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
A, Mezzabotta L, Bugianesi E. Systemic complications of nonalcoholic fatty liver disease: when the liver is not an innocent bystander. Semin Liver Dis. 2015;35(3):236-249.
More news about: NOVO NORDISK INC.